Stage II/III Colorectal Cancer Recurrence

Description

This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.

Conditions

Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Recurrent

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.

Predicting Recurrence-Free Survival in Stage III and High-Risk Stage II Colorectal Cancer After Curative-Intent Treatment

Stage II/III Colorectal Cancer Recurrence

Condition
Colorectal Cancer
Intervention / Treatment

-

Contacts and Locations

Monrovia

City of Hope Medical Center, Monrovia, California, United States, 91016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Stage II (high-risk) or III colorectal cancer (TNM classification, 8th edition).
  • * Received standard diagnostic, staging, and therapeutic procedures as per local guidelines
  • * Received stage-specific curative-intent resection followed by adjuvant chemotherapy.
  • * Confirmed cancer-free survivorship confirmed at the time of study inclusion.
  • * Lack of written informed consent.
  • * Development of recurrence in the first 6 months following adjuvant chemotherapy completion.
  • * Hereditary colorectal cancer syndromes (identified through genetic testing)
  • * Inflammatory bowel diseases

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

City of Hope Medical Center,

Ajay Goel, PhD, PRINCIPAL_INVESTIGATOR, City of Hope Medical Center

Study Record Dates

2025-03-15